EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 87 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Highlights the Importance of a Strong EU Commitment Towards Robust Science and Innovation Policies Following Meeting of EU Research Ministers on 29 May... Metastatic Breast Cancer: ESMO Clinical Practice Guideline EMA Recommends Extending Indications for Decitabine / Cedazuridine MOST POPULAR BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions May 18, 2020 Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast... November 13, 2020 COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms November 15, 2022 20 Adorable Tiny Homes That Are Perfect For A Peaceful Weekend... July 9, 2019 Load more HOT NEWS Turning the Life Sciences Vision into reality Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... Molecular Profiling with Targeted Panel Tests that Includes Fusion Detection Has... Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant,...
